Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2013-08-12
Target enrollment:
Participant gender:
Summary
This study evaluated the efficacy of oral panobinostat in participants with
refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with
high dose chemotherapy and autologous stem cell transplant. Safety of panobinostat also was
assessed. Other markers that may correlate with efficacy or safety were explored.